Alimatravir vs Doravirine/islatravir (Idvynso)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV-1 Reverse Transcriptase · full HIV pipeline
Alimatravir
Developed by Merck & Co.
NCT06045507 · Phase 2 · completed
This randomized, double-blind, placebo-controlled Phase 2a study gave oral MK-8527 (alimatravir) once monthly at three doses or placebo to 352 adults at low risk of HIV-1 infection. Its stated purpose was safety, tolerability and pharmacokinetics, and both registered primary outcomes are adverse-event counts with no formal efficacy test, so there is no met or missed result. Source: CT.gov posted results. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With ≥1 Adverse Event (AE)" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: January 2027 · NCT07600775 (registry estimate)
Reported efficacy
Number of Participants With ≥1 Adverse Event (AE) (Up to ~28 weeks); Number of Participants Discontinuing Study Therapy Due to Adverse Event (AE) (Up to ~20 weeks): Primary outcomes, safety (no formal efficacy test): participants with at least one adverse event 62/101 (3 mg), 69/101 (6 mg) and 66/99 (12 mg) monthly MK-8527 vs 31 on placebo; discontinuation due to an adverse event 0, 2 and 1 vs 2 (CT.gov posted results). (not_applicable)
Result source: NCT06045507
Doravirine/islatravir (Idvynso)
Marketed by Merck & Co.
NCT05631093 · Phase 3 · active, not recruiting
Trial 051 randomized 551 virologically suppressed adults with HIV-1 2:1, open-label, to switch to once-daily doravirine/islatravir or stay on their baseline antiretroviral regimen. The primary efficacy endpoint was the proportion with HIV-1 RNA at or above 50 copies/mL at Week 48, tested for non-inferiority with a 4-percentage-point margin. The rate was 1.4% after the switch and 4.9% on baseline therapy (difference -3.58, 95% CI -7.81 to -0.77), so non-inferiority was shown and the primary endpoint was met. The other registered primaries are adverse-event rates. Source: ClinicalTrials.gov posted results and the IDVYNSO US label, section 14.
Next expected readout: May 2029 · NCT04776252 (registry estimate)
Reported efficacy
Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) ≥50 Copies/mL at Week 48; Percentage of Participants Who Experience Adverse Events (AEs) Through Week 48; Percentage of Participants Who Discontinue Study Intervention Due to AEs Through Week 48: HIV-1 RNA at or above 50 copies/mL at Week 48 (FDA Snapshot), switch to doravirine/islatravir (n=342) vs staying on bictegravir/emtricitabine/tenofovir alafenamide (n=171): 1.5% vs 0.6%; risk difference 0.88 percentage points (95% CI -1.86 to 2.90), non-inferiority p=0.003 against a 4-point margin (CT.gov posted results). (met)
Result source: NCT05630755
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Alimatravir | Doravirine/islatravir (Idvynso) |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Trial running · NCT07044297 | —Trial running · NCT05630755 |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Trial running · NCT07044297 | —Trial running · NCT05630755 |
| CD4 count, change (week 48) | —Trial running · NCT07044297 | —Trial running · NCT05630755 |
HIV-1 RNA below 50 copies/mL (week 48)
- Alimatravir
- —Trial running · NCT07044297
- Doravirine/islatravir (Idvynso)
- —Trial running · NCT05630755
HIV-1 RNA 50 copies/mL or more (week 48)
- Alimatravir
- —Trial running · NCT07044297
- Doravirine/islatravir (Idvynso)
- —Trial running · NCT05630755
CD4 count, change (week 48)
- Alimatravir
- —Trial running · NCT07044297
- Doravirine/islatravir (Idvynso)
- —Trial running · NCT05630755
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Alimatravir: 3 of 4 rows · Doravirine/islatravir (Idvynso): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Alimatravir |
|---|---|
| Dropout rate | 2%12 mg QMa NCT06045507 · Phase 2 show 9 more results4.9%6 mg QM NCT06045507 · Phase 2 8.9%3 mg QM NCT06045507 · Phase 2 0%1.0 mg NCT05494736 · Phase 1 · registry result, not featured evidence 0%0.5 mg NCT05494736 · Phase 1 · registry result, not featured evidence 0%0.25 mg NCT05494736 · Phase 1 · registry result, not featured evidence —0.25 mg NCT05494736 · Phase 1 · registry result, not featured evidence 0%10 mg NCT03615183 · Phase 1 · registry result, not featured evidence 0%3 mg NCT03615183 · Phase 1 · registry result, not featured evidence 0%1 mg NCT03615183 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —12 mg QMa NCT06045507 · Phase 2 show 9 more results—6 mg QM NCT06045507 · Phase 2 —3 mg QM NCT06045507 · Phase 2 —1.0 mg NCT05494736 · Phase 1 · registry result, not featured evidence —0.5 mg NCT05494736 · Phase 1 · registry result, not featured evidence —0.25 mg NCT05494736 · Phase 1 · registry result, not featured evidence —0.25 mg NCT05494736 · Phase 1 · registry result, not featured evidence —10 mg NCT03615183 · Phase 1 · registry result, not featured evidence —3 mg NCT03615183 · Phase 1 · registry result, not featured evidence —1 mg NCT03615183 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 1%12 mg QMa NCT06045507 · Phase 2 show 9 more results0%6 mg QM NCT06045507 · Phase 2 2%3 mg QM NCT06045507 · Phase 2 0%1.0 mg NCT05494736 · Phase 1 · registry result, not featured evidence 0%0.5 mg NCT05494736 · Phase 1 · registry result, not featured evidence —0.25 mg NCT05494736 · Phase 1 · registry result, not featured evidence 0%0.25 mg NCT05494736 · Phase 1 · registry result, not featured evidence 0%10 mg NCT03615183 · Phase 1 · registry result, not featured evidence 0%3 mg NCT03615183 · Phase 1 · registry result, not featured evidence 0%1 mg NCT03615183 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 12 mg QMa upper respiratory tract infection 10.1% (placebo 12.2%) fatigue 7.1% (placebo 6.1%) lymphocyte count decreased 6.1% (placebo 2%) NCT06045507 · Phase 2 show 8 more results6 mg QM upper respiratory tract infection 9.9% (placebo 12.2%) fatigue 7.9% (placebo 6.1%) nausea 7.9% (placebo 2%) NCT06045507 · Phase 2 3 mg QM upper respiratory tract infection 15.8% (placebo 12.2%) headache 8.9% (placebo 0%) cough 5% (placebo 0%) NCT06045507 · Phase 2 1.0 mg headache 25% blood pressure increased 12.5% conjunctivitis allergic 12.5% NCT05494736 · Phase 1 · registry result, not featured evidence 0.5 mg anogenital warts 16.7% carbuncle 16.7% dermatitis contact 16.7% NCT05494736 · Phase 1 · registry result, not featured evidence 0.25 mg dyspepsia 16.7% dyspnoea 16.7% headache 16.7% NCT05494736 · Phase 1 · registry result, not featured evidence 10 mg dizziness 0% insomnia 0% pharyngitis 0% NCT03615183 · Phase 1 · registry result, not featured evidence 3 mg dizziness 16.7% insomnia 16.7% pharyngitis 16.7% NCT03615183 · Phase 1 · registry result, not featured evidence 1 mg dizziness 0% insomnia 0% pharyngitis 0% NCT03615183 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Alimatravir
show 2 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alimatravir's landscape · Doravirine/islatravir (Idvynso)'s landscape